Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Efavirenz
Bristol-Myers Squibb Pharmaceuticals Ltd
J05AG03
Efavirenz
600mg
Tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 05030100; GTIN: 5012712003144
1 PACKAGE LEAFLET: INFORMATION FOR THE USER SUSTIVA 600 MG FILM-COATED TABLETS efavirenz READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What SUSTIVA is and what it is used for 2. What you need to know before you take SUSTIVA 3. How to take SUSTIVA 4. Possible side effects 5. How to store SUSTIVA 6. Contents of the pack and other information 1. WHAT SUSTIVA IS AND WHAT IT IS USED FOR SUSTIVA, which contains the active substance efavirenz, belongs to a class of antiretroviral medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It is an ANTIRETROVIRAL MEDICINE THAT FIGHTS HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) infection by reducing the amount of the virus in blood. It is used by adults, adolescents and children 3 months of age and older and weighing at least 3.5 kg. Your doctor has prescribed SUSTIVA for you because you have HIV infection. SUSTIVA taken in combination with other antiretroviral medicines reduces the amount of the virus in the blood. This will strengthen your immune system and reduce the risk of developing illnesses linked to HIV infection. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE SUSTIVA DO NOT TAKE SUSTIVA IF YOU ARE ALLERGIC to efavirenz or any of the other ingredients of this medicine (listed in section 6). Contact your doctor or pharmacist for advice. IF YOU HAVE SEVERE LIVER DISEASE. IF YOU HAVE A HEART CONDITION, SUCH AS CHANGES IN THE RHYTHM OR RATE OF THE HEART BEAT, A SLOW HEART BEAT, OR SEVERE HEART DISEASE. Read the complete document
OBJECT 1 SUSTIVA 600 MG FILM-COATED TABLETS Summary of Product Characteristics Updated 04-Jan-2018 | Bristol-Myers Squibb Pharmaceuticals limited 1. Name of the medicinal product SUSTIVA 600 mg film-coated tablets 2. Qualitative and quantitative composition Each film-coated tablet contains 600 mg of efavirenz. Excipient with known effect Each film-coated tablet contains 249.6 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. Pharmaceutical form Film-coated tablet Dark yellow, capsule-shaped, printed with “SUSTIVA” on both sides. 4. Clinical particulars 4.1 Therapeutic indications SUSTIVA is indicated in antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected adults, adolescents and children 3 months of age and older and weighing at least 3.5 kg. SUSTIVA has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm 3 , or after failure of protease inhibitor (PI) containing regimens. Although cross-resistance of efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI based combination therapy after failure of regimens containing SUSTIVA. For a summary of clinical and pharmacodynamic information, see section 5.1. 4.2 Posology and method of administration Therapy should be initiated by a physician experienced in the management of HIV infection. Posology Efavirenz must be given in combination with other antiretroviral medicines (see section 4.5). In order to improve the tolerability of nervous system adverse reactions, bedtime dosing is recommended (see section 4.8). _Adults and adolescents over 40 kg_ The recommended dose of efavirenz in combination with nucleoside analogue reverse transcriptase inhibitors (NRTIs) with or without a PI (see section 4.5) is 600 mg orally, once daily. Efavirenz film-coated tablets are not suitable for children weighing less than 40 kg. Efavirenz hard capsules are available for these patients. _Dose Read the complete document